1/17/2013

Boehringer Ingelheim's experimental drug afatinib obtained priority-review status from the FDA as a treatment for locally advanced or metastatic nonsmall-cell lung cancer in patients with epidermal growth factor receptor mutations. A decision is expected by the third quarter.

Full Story:
PharmaTimes (U.K.)

Related Summaries